COMP <GO>
CORT vs LLY // FORWARD P/E MULTIPLE
Corcept Therapeutics Incorporated (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: CORT 3
— LLY 11
▲ FORWARD P/E MULTIPLE LEADER: LLY
LAST: $85.95 (-0.38%) • MKT CAP: $9.29B
forward-pe
78.3x
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
forward-pe
26.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CORT VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CORT | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 83.64% | +12.36 | CORT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.80% | 32.36% | -27.56 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 36.4x | +58.58 | LLY | /valuation <GO> |
| Free Cash Flow Yield | 1.53% | 2.30% | -0.77 | LLY | /fcf-yield <GO> |
| Operating Margin | 5.90% | 40.21% | -34.31 | LLY | /operating-margins <GO> |
| Net Profit Margin | 13.10% | 31.90% | -18.80 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 12.80% | 45.51% | -32.71 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 9.29 | +16.71 | CORT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.9 | 66.6 | -35.70 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.51 | +0.37 | CORT | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 78.3x | 26.3x | +52.05 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.29B | $1.29T | -$1.28T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CORT REV | LLY REV | CORT GROSS % | LLY GROSS % | CORT FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $761.4M | $65.18B | 98.3% | 83.0% | $141.8M | $16.81B |
| FY 2024 | $675.0M | $45.04B | 98.4% | 81.3% | $196.1M | $8.82B |
| FY 2023 | $482.4M | $34.12B | — | 79.3% | $105.0M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CORT // BETA 0.88
LLY // BETA 0.51